Advanced medical Optics (NYSE:AVO)
Historical Stock Chart
From May 2019 to May 2024
Advanced Medical Optics' ReZoom Lens to Benefit Cataract Patients
Under New CMS Ruling on Presbyopic IOLs
SANTA ANA, Calif., May 11 /PRNewswire-FirstCall/ -- Advanced Medical Optics,
(AMO) (NYSE:AVO) a global leader in ophthalmic surgical devices and eye care
products, announced today that the Centers for Medicare and Medicaid Services
(CMS) ruled that Medicare beneficiaries may choose to receive
presbyopia-correcting intraocular lenses (IOLs) for an additional fee as part
of cataract surgery. These lenses, including AMO's ReZoom(TM) multifocal IOL,
provide vision for distance, intermediate and near ranges.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO)
AMO pioneered the concept of an IOL that provides distance, intermediate and
near vision in the late 1990s when it received the first-ever FDA approval for
a multifocal lens. In March 2005, AMO received FDA approval for its
second-generation multifocal technology, the ReZoom(TM) IOL. In a 215-patient
European study, 93 percent of ReZoom(TM) patients reported never or only
occasionally having to wear glasses.
"This provides an important new opportunity for Medicare cataract patients to
enjoy a full range of distance, intermediate and near vision after surgery,"
said Jim Mazzo, president and CEO of AMO."
The ReZoom(TM) IOL features Balanced View Optics(TM) technology that
distributes light over five optic zones for enhanced restoration of visual
function for reduced spectacle dependence. This allows the ReZoom(TM) IOL to
match its performance characteristics with the lifestyle demands of the
patients.
About Advanced Medical Optics (AMO)
AMO is a global leader in the development, manufacturing and marketing of
ophthalmic surgical and eye care products. The company focuses on developing a
broad suite of innovative technologies and devices to address a wide range of
eye disorders. Products in the ophthalmic surgical line include intraocular
lenses, phacoemulsification systems, viscoelastics, microkeratomes and related
products used in cataract and refractive surgery. AMO owns or has the rights
to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R),
Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM)
intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM)
phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and
Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the
Baerveldt(R) glaucoma shunt. Products in the contact lens care line include
disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops. Among the contact lens care product brands the company possesses are
COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F,
Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R)
and blink(TM) branded products. Amadeus is a licensed product of, and a
trademark of, SIS, Ltd. OptiEdge(TM) is a registered trademark of Ocular
Sciences. AMO is based in Santa Ana, California, and employs approximately
3,000 worldwide. The company has operations in about 20 countries and markets
products in approximately 60 countries. For more information, visit the
company's Web site at http://www.amo-inc.com/.
Forward-Looking Statements
This press release contains forward-looking statements about AMO and its
business such as Mr. Mazzo's statements and statements about AMO's sales of
ReZoom(TM) IOL. Any statements in this press release that refer to AMO's
estimated or anticipated future results are forward-looking statements. All
forward-looking statements in this press release reflect AMO's current analysis
of existing trends and information and represent AMO's judgment only as of the
date of this press release. Actual results may differ from current
expectations based on a number of factors affecting AMO's business, including
risks of technology development failures and product feasibility; the execution
of strategic initiatives; the uncertainties associated with intellectual
property protection for these products; and the actual benefit, implementation
and modification of the CMS ruling. Therefore, the reader is cautioned not to
rely on these forward-looking statements. AMO disclaims any intent or
obligation to update these forward-looking statements.
Additional information concerning these and other risk factors may be found in
previous financial press releases issued by AMO. AMO's public periodic filings
with the Securities and Exchange Commission, including the discussion under the
heading "Certain Factors and Trends Affecting AMO and its Businesses" in AMO's
2005 Form 10-Q filed in April 2005 include information concerning these and
other risk factors. Copies of press releases and additional information about
AMO are available at http://www.amo-inc.com/, or you can contact the AMO
Investor Relations Department by calling 714-247-8348.
Advanced Medical Optics, Inc.
Investors:
Sheree Aronson
(714) 247-8290
Media:
Steve Chesterman
(714) 247-8711
http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO
http://photoarchive.ap.org/
DATASOURCE: Advanced Medical Optics
CONTACT: investors, Sheree Aronson, +1-714-247-8290,
, or media, Steve Chesterman, +1-714-247-8711,
, both of Advanced Medical Optics
Web site: http://www.amo-inc.com/